Is HOOD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of HOOD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate HOOD's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate HOOD's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HOOD?
Other financial metrics that can be useful for relative valuation.
Key Statistics | |
---|---|
Enterprise Value/Revenue | n/a |
Enterprise Value/EBITDA | n/a |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does HOOD's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 3.5x | ||
XP XP | 4.9x | 17.4% | US$14.0b |
LPLA LPL Financial Holdings | 1.9x | 8.3% | US$19.6b |
RJF Raymond James Financial | 2.3x | 6.5% | US$26.6b |
HLI Houlihan Lokey | 4.8x | 14.2% | US$8.8b |
HOOD Robinhood Markets | 9.4x | 8.3% | US$17.5b |
Price-To-Sales vs Peers: HOOD is expensive based on its Price-To-Sales Ratio (9.4x) compared to the peer average (3.5x).
Price to Earnings Ratio vs Industry
How does HOOD's PE Ratio compare vs other companies in the US Capital Markets Industry?
0 Companies | Price / Earnings | Estimated Growth | Market Cap |
---|---|---|---|
Industry Avg. | n/a | 15.9% | |
n/a | n/a | n/a | |
Fetching data
0 Companies | Price / Earnings | Estimated Growth | Market Cap |
---|---|---|---|
Industry Avg. | n/a | 15.9% | |
n/a | n/a | n/a |
No more companies
Price-To-Sales vs Industry: HOOD is expensive based on its Price-To-Sales Ratio (9.4x) compared to the US Capital Markets industry average (3.3x).
Price to Sales Ratio vs Fair Ratio
What is HOOD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 9.4x |
Fair PS Ratio | 4.2x |
Price-To-Sales vs Fair Ratio: HOOD is expensive based on its Price-To-Sales Ratio (9.4x) compared to the estimated Fair Price-To-Sales Ratio (4.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | US$20.01 | US$16.08 -19.6% | 33.1% | US$30.00 | US$11.00 | n/a | 15 |
Mar ’25 | US$16.58 | US$13.88 -16.3% | 24.9% | US$25.00 | US$11.00 | n/a | 14 |
Feb ’25 | US$10.91 | US$12.74 +16.8% | 25.6% | US$23.00 | US$9.60 | n/a | 14 |
Jan ’25 | US$12.74 | US$11.61 -8.9% | 29.2% | US$23.00 | US$9.00 | n/a | 14 |
Dec ’24 | US$9.32 | US$11.39 +22.2% | 30.6% | US$23.00 | US$9.00 | n/a | 14 |
Nov ’24 | US$9.08 | US$12.19 +34.3% | 31.1% | US$24.00 | US$9.00 | n/a | 13 |
Oct ’24 | US$9.81 | US$12.85 +31.0% | 31.3% | US$25.00 | US$9.00 | n/a | 12 |
Sep ’24 | US$11.11 | US$12.90 +16.1% | 30.9% | US$25.00 | US$9.00 | n/a | 12 |
Aug ’24 | US$12.87 | US$11.92 -7.4% | 35.7% | US$25.00 | US$8.00 | n/a | 12 |
Jul ’24 | US$9.98 | US$11.58 +16.1% | 37.5% | US$25.00 | US$8.00 | n/a | 12 |
Jun ’24 | US$9.02 | US$11.58 +28.4% | 37.5% | US$25.00 | US$8.00 | n/a | 12 |
May ’24 | US$8.82 | US$11.63 +31.9% | 37.1% | US$25.00 | US$8.10 | n/a | 12 |
Apr ’24 | US$9.71 | US$11.63 +19.7% | 37.2% | US$25.00 | US$8.00 | n/a | 12 |
Mar ’24 | US$9.73 | US$12.00 +23.3% | 35.0% | US$25.00 | US$8.00 | US$16.58 | 12 |
Feb ’24 | US$10.78 | US$11.46 +6.3% | 38.6% | US$25.00 | US$8.00 | US$10.91 | 12 |
Jan ’24 | US$8.14 | US$12.42 +52.5% | 40.5% | US$28.00 | US$8.00 | US$12.74 | 12 |
Dec ’23 | US$9.87 | US$12.42 +25.8% | 40.9% | US$28.00 | US$7.00 | US$9.32 | 12 |
Nov ’23 | US$11.92 | US$10.44 -12.4% | 15.6% | US$13.00 | US$7.00 | US$9.08 | 11 |
Oct ’23 | US$10.10 | US$11.50 +13.9% | 45.5% | US$28.00 | US$7.00 | US$9.81 | 12 |
Sep ’23 | US$9.63 | US$11.50 +19.4% | 45.5% | US$28.00 | US$7.00 | US$11.11 | 12 |
Aug ’23 | US$9.04 | US$11.19 +23.8% | 47.9% | US$28.00 | US$5.00 | US$12.87 | 13 |
Jul ’23 | US$8.18 | US$12.31 +50.5% | 56.9% | US$36.00 | US$5.00 | US$9.98 | 14 |
Jun ’23 | US$9.37 | US$13.60 +45.1% | 47.1% | US$36.00 | US$10.00 | US$9.02 | 14 |
May ’23 | US$9.81 | US$14.46 +47.4% | 48.0% | US$36.00 | US$10.00 | US$8.82 | 14 |
Apr ’23 | US$13.50 | US$17.21 +27.5% | 48.2% | US$45.00 | US$11.00 | US$9.71 | 14 |
Mar ’23 | US$11.77 | US$17.38 +47.7% | 49.4% | US$45.00 | US$11.00 | US$9.73 | 13 |
Analyst Forecast: Target price is lower than the current share price.
Discover undervalued companies
Price
7D
1Y
Mkt cap
PS
E.Growth
Analysts Target
Price
7D
1Y
Mkt cap
PS
E.Growth
Analysts Target
Price
7D
1Y
Mkt cap
PS
E.Growth
Analysts Target
Price
7D
1Y
Mkt cap
PS
E.Growth
Analysts Target